Oncology Company Announces Promising Ovarian Cancer Study Results

Predictive Oncology Inc. (NASDAQ: POAI), a company in AI-driven drug discovery and biologics, has announced significant positive results from a retrospective study conducted in collaboration with UPMC Magee-Womens Hospital. These results are set to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 31 to June 4, 2024, in Chicago, IL. The presentation will provide insights into the use of machine learning (ML) models to predict survival outcomes for ovarian cancer patients, potentially transforming clinical management and treatment personalization. $Predictive Oncology(POAI.US)$